Výsledky vyhledávání

I41 Post-marketing adverse events (AES) associated with tetrabenazine (TBZ): findings using FDA’s adverse event reporting system (FAERS)

Autor: Mo Dimbil, Abril Giron, Sanjay Gandhi, Ravi Iyer, Daniel O. Claassen, Keith B. Hoffman, Lisa De Boer

Publikováno v: Journal of Neurology, Neurosurgery & Psychiatry. 87:A73.2-A73

Background In clinical trials of patients with Huntington’s disease (HD), treatment with TBZ resulted in more neuropsychiatric AEs compared to placebo, including insomnia, somnolence, anxiety, depression, and agitation. Aim To summarise post-market

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::87d60fcd24266dc4b2dc705c75a83762
https://doi.org/10.1136/jnnp-2016-314597.206

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání